Judy Hemberger | PhD MBA – CEO
Dr. Hemberger has more than thirty years of experience in the pharmaceutical industry. She was co-founder and COO of Pharmion Corporation prior to its sale to Celgene for $2.9 billion. Dr. Hemberger’s expertise includes clinical development, global regulatory and early commercialization of pharmaceutical products. She is a demonstrated leader of both domestic and international operations. Dr. Hemberger is highly effective at raising capital for start-up ventures, including private equity, initial public offerings, and secondary placements. She is a board member of a wide variety of health care companies, public and private, and has served as a consultant and partner in venture capital firms. In addition to her tenure at Pharmion, Dr. Hemberger has served as CEO of Zosano (formerly Macroflux) and as a Venture Partner for Nomura Phase 4 Ventures. She has served as a director on over 16 health care boards of directors. Dr. Hemberger is a graduate of Mt. St. Scholastic College (BS), University of Missouri (PhD), and Business Rockhurst College (MBA).
Tin Tin Su | PhD – CSO and Co-Founder
Dr. Su has more than twenty years’ experience in radiation biology and genetics. A full professor at the University of Colorado at Boulder and head of the Su Lab, Dr. Su has a proven track record in securing external funds from Federal, State, and non-profit organizations. Dr. Su co-founded SuviCa. She also devised and patented a whole-animal screening technology to quickly and efficiently identify potential drug candidates. Dr. Su is an expert in radiation biology and genetic models of cancer. A current member of the editorial board for Current Biology, Dr. Su has authored more than fifty scientific papers. Dr. Su is a graduate of Mt. Holyoke College (BA) and Carnegie-Mellon University (PhD) and did post-doctoral work at the University of California, San Francisco.
Bert Pronk | PhD – VP Preclinical Development
Dr. Pronk has over twenty-five years’ of experience in research and drug development for various oncology indications in academic and industry environments; from basic research and discovery to IND/NDA/MAA filings. He has managed research groups in discovery and early development as well as external collaborations with academic investigators and contract research organizations. Prior to joining SuviCa, Dr. Pronk was Senior Director of Pre-Clinical Development and Clinical Pharmacology at Allos Therapeutics, where he oversaw pre-clinical and clinical pharmacology development of pralatrexate, contributing to a successful NDA and approval by the FDA. Dr. Pronk also held research management positions at Chiron Corporation, Atugen AG, and Serenex. Dr. Pronk is a graduate of the Ghijsen Institute (BS) and Utrecht University (PhD), the Netherlands, and did post-doctoral work at the University of California, San Francisco.
Wendi Pevler | MBA – CFO
Wendi Pevler has twenty years’ experience working with small and mid-sized companies in accounting, accounts receivable, and as CFO, specifically in academic research and biotech startups. Ms. Pevler is a graduate of CU Denver, MBA (Finance), MS (Management & Organization).
Callie Weiant | VP Business Development
Callie Weiant is responsible for internal operations and business development. After practicing law at McKenna, Long & Aldridge (currently Dentons), Ms. Weiant co-founded a consumer products company and has consulted for start-ups in areas of business development, operations and marketing. She is a graduate of Amherst College (BA) and New York University School of Law.